Literature DB >> 9029028

A new c-kit mutation in a case of aggressive mast cell disease.

J M Pignon1, S Giraudier, P Duquesnoy, H Jouault, M Imbert, W Vainchenker, J P Vernant, M Tulliez.   

Abstract

Systemic mast cell disease (SMCD) is a disorder characterized by a mast cell proliferation in various tissues. Mast cells express the c-kit proto-oncogene. A few cases of c-kit mutations have been described in SMCD. We report an aggressive SMCD in a patient who presented with a bone marrow infiltration by abnormal mast cells. Molecular studies of mast cell DNA and RNA revealed a new c-kit heterozygous mutation (Asp820Gly). This mutation leads to a drastic amino-acid change and is located close to the highly oncogenic Asp816Val. These findings suggest that the Asp820Gly has a potential role in c-kit activation.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9029028     DOI: 10.1046/j.1365-2141.1997.d01-2042.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  18 in total

Review 1.  Systemic mast cell activation disease: the role of molecular genetic alterations in pathogenesis, heritability and diagnostics.

Authors:  Britta Haenisch; Markus M Nöthen; Gerhard J Molderings
Journal:  Immunology       Date:  2012-11       Impact factor: 7.397

Review 2.  Anaphylaxis as a clinical manifestation of clonal mast cell disorders.

Authors:  A Matito; I Alvarez-Twose; J M Morgado; L Sánchez-Muñoz; A Orfao; L Escribano
Journal:  Curr Allergy Asthma Rep       Date:  2014-08       Impact factor: 4.806

3.  Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412.

Authors:  Joseph D Growney; Jennifer J Clark; Jennifer Adelsperger; Richard Stone; Doriano Fabbro; James D Griffin; D Gary Gilliland
Journal:  Blood       Date:  2005-03-24       Impact factor: 22.113

4.  Detection of c-kit mutation Asp 816 to Val in microdissected bone marrow infiltrates in a case of systemic mastocytosis associated with chronic myelomonocytic leukaemia.

Authors:  K Sotlar; T Marafioti; H Griesser; J Theil; C Aepinus; R Jaussi; H Stein; P Valent; H P Horny
Journal:  Mol Pathol       Date:  2000-08

5.  c-kit Mutations in patients with childhood-onset mastocytosis and genotype-phenotype correlation.

Authors:  Hirokatsu Yanagihori; Noritaka Oyama; Koichiro Nakamura; Fumio Kaneko
Journal:  J Mol Diagn       Date:  2005-05       Impact factor: 5.568

Review 6.  Comprehensive Analysis of Acquired Genetic Variants and Their Prognostic Impact in Systemic Mastocytosis.

Authors:  Oscar González-López; Javier I Muñoz-González; Alberto Orfao; Iván Álvarez-Twose; Andrés C García-Montero
Journal:  Cancers (Basel)       Date:  2022-05-18       Impact factor: 6.575

7.  The structural insights of stem cell factor receptor (c-Kit) interaction with tyrosine phosphatase-2 (Shp-2): an in silico analysis.

Authors:  Soumya Pati; Gangenahalli U Gurudutta; Om P Kalra; Asok Mukhopadhyay
Journal:  BMC Res Notes       Date:  2010-01-22

8.  Regulation of normal and neoplastic human mast cell development in mastocytosis.

Authors:  Dean D Metcalfe
Journal:  Trans Am Clin Climatol Assoc       Date:  2005

9.  KIT mutations are common in testicular seminomas.

Authors:  Kathleen Kemmer; Christopher L Corless; Jonathan A Fletcher; Laura McGreevey; Andrea Haley; Diana Griffith; Oscar W Cummings; Cecily Wait; Ajia Town; Michael C Heinrich
Journal:  Am J Pathol       Date:  2004-01       Impact factor: 4.307

Review 10.  Multi-stage Friend murine erythroleukemia: molecular insights into oncogenic cooperation.

Authors:  Françoise Moreau-Gachelin
Journal:  Retrovirology       Date:  2008-11-04       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.